Deflazacort Should Not Be Used in Pregnancy Without Compelling Indication
In a patient with one-month amenorrhea (presumed pregnancy until proven otherwise) presenting with urticaria, deflazacort should be avoided and safer alternatives should be prioritized. The amenorrhea strongly suggests possible pregnancy, and corticosteroids carry risks during pregnancy, particularly in the first trimester.
Clinical Approach to This Patient
Step 1: Confirm Pregnancy Status Immediately
- Obtain a pregnancy test before prescribing any medication 1
- One month of amenorrhea in a reproductive-age woman must be considered pregnancy until proven otherwise
- If pregnancy is confirmed, the treatment approach changes significantly
Step 2: First-Line Treatment for Urticaria (Regardless of Pregnancy Status)
Non-sedating H1-antihistamines are the cornerstone of urticaria management 2:
- Loratadine or cetirizine are preferred in pregnancy as they are FDA Pregnancy Category B drugs, with no evidence of fetal harm despite lack of well-controlled human studies 2
- Chlorphenamine has the longest safety record in pregnancy and is often chosen by UK clinicians when antihistamine therapy is necessary 2
- Best practice is to avoid all antihistamines in pregnancy, especially during the first trimester, though none has been proven teratogenic in humans 2
- Hydroxyzine is specifically contraindicated in early pregnancy 2
Step 3: Role of Corticosteroids in Urticaria
Short-course oral corticosteroids may shorten acute urticaria duration (e.g., prednisolone 50 mg daily for 3 days in adults, though lower doses are often effective) 2:
- However, long-term oral corticosteroids should NOT be used in chronic urticaria (Strength of recommendation A) except in very selected cases under specialist supervision 2
- The British Journal of Dermatology guidelines make no specific mention of deflazacort for urticaria management 2
Step 4: Deflazacort-Specific Concerns
The FDA label for deflazacort does not provide specific pregnancy category information in the provided evidence, but general corticosteroid precautions apply 3:
- Deflazacort causes immunosuppression, increases infection risk, and has multiple systemic effects including cardiovascular, gastrointestinal, behavioral, and bone-related adverse effects 3
- One case report documented amenorrhea as a side effect of deflazacort (along with 14 kg weight gain), leading to treatment discontinuation 4
- Deflazacort has been studied primarily for chronic inflammatory conditions (sarcoidosis, rheumatoid arthritis, Duchenne dystrophy) rather than acute urticaria 4, 5
Recommended Treatment Algorithm
If Pregnancy Test is Negative:
- Start with non-sedating H1-antihistamines (cetirizine, loratadine, fexofenadine) at standard doses 2, 6
- If inadequate control after 2-4 weeks, increase antihistamine dose up to 4-fold 6, 7
- If symptoms are severe and intolerable, consider short-course prednisolone (3-7 days) rather than deflazacort 2
- For refractory cases, add leukotriene receptor antagonists (montelukast) 2, 8
If Pregnancy Test is Positive:
- Prioritize loratadine or cetirizine (FDA Category B) as first-line treatment 2
- Avoid deflazacort and other corticosteroids unless absolutely necessary for maternal health
- If corticosteroids are essential, use the lowest effective dose of prednisolone for the shortest duration possible
- Consult obstetrics for shared decision-making regarding risk-benefit analysis
Key Clinical Pitfalls
- Never assume amenorrhea is unrelated to pregnancy in reproductive-age women—always test first 1
- Deflazacort is not a standard treatment for urticaria and lacks specific evidence for this indication 2, 7
- Antihistamines, not corticosteroids, are first-line therapy for both acute and chronic urticaria 2, 6, 7
- One case report showed acute urticaria actually caused by oral methylprednisolone in a patient who had previously tolerated deflazacort, highlighting that corticosteroids themselves can trigger urticaria 9